Group 4 Created with Sketch.

The MattCorc Podcast

Play All
27 Subscribers
Share Path Report
rss rss .
A daily, 5-10 minute, podcast where we talk about risk and investing. Find out more at mattcorc.com or shoot me an email at matt@mattcorc.com. I would love to hear any feedback, including topic suggestions and insurance questions. If you would like to join me on an episode, send me an email. Continue Reading >>
A daily, 5-10 minute, podcast where we talk about risk and investing. Find out more at mattcorc.com or shoot me an email at matt@mattcorc.com. I would love to hear any feedback, including topic suggestions and insurance questions. If you would like to join me on an episode, send me an email. << Show Less
Featured Audio
Where does the market go from here? Will retail investors sell? We talk about the recent market turmoil and how that will impact investor actions. Will investors stick to their guns or succumb and sell if the market continues to sell off. A few comments on Medtronic’s settlement and how insurance could have been implemented to reduce the financial burden for Medtronic.
Newest Audio
Where does the market go from here? Will retail investors sell? We talk about the recent market turmoil and how that will impact investor actions. Will investors stick to their guns or succumb and sell if the market continues to sell off. A few comments on Medtronic’s settlement and how insurance could have been implemented to reduce the financial burden for Medtronic.
What’s the deal with GE? GE has seen its market cap decrease by over $200B since 2016 and it now trades at around $8. Is this the correct value or should it be higher or perhaps lower?
We changed our name and Amazon announced their new locations! Why we changed our name to the MattCorc Podcast. Who is taking the most risk with the Amazon headquarters, Amazon or the local/state government? What is Waymo? The first autonomous ride hailing service is getting ready to launch in Arizona.
A $500 Million Biotech IPO. Amarin Data Moderna plans the biggest biotech IPO ever and we learn more about Amarin’s clinical study. Was mineral oil the best choice of placebo? Lessons we can learn from Amarin about D&amp;O insurance.
Herd Mentality. Why D&O benchmarking is a sales ploy. What to use to make a more informed decision. I talk about how brokers use benchmarking to sell you more D&O insurance. Brokers take advantage of herd mentality so insurers buy more D&O than they need.
Why cost should only be one consideration Cost and its importance are discussed. Minor differences in coverage can cause major headaches when you have a claim.
S&P Companies not as negative; Gene Therapy manufacturing is stretched thin Happy national doughnut day! Fewer companies in the S&amp;P are providing negative guidance. What does this mean? How CFOs are protecting their balance sheets in the event their manufacturing is disrupted.
Lessons from Halloween when your kids have peanut allergies Why is Aimmune (AIMT) up today? Is it because Halloween reminded investors how many types of candy have peanuts in them? A lesson on how to make sure you aren’t missing significant coverage gaps in your insurance program. Hint: I learned it from checking my kids Halloween candy.
Swimming and the Dow Jones How my first time swimming in a lap pool in years was a good metaphor for today’s market and some other interesting facts on the financial markets.
Load More Audio